Amarin Pharma, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$18Mgeneral payments (2019-2025)
$58Kresearch payments (2019-2025)
67,936clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| John Osborne | Grapevine, TX | Cardiovascular Disease | $283,073.30 |
| Eliot Brinton | Salt Lake City, UT | Endocrinology, Diabetes & Metabolism | $246,257.12 |
| John Nelson | Fresno, CA | Internal Medicine | $239,000.47 |
| William Cromwell | Raleigh, NC | Family Medicine | $236,656.23 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $222,881.92 |
| John Gerald Canto | Lakeland, FL | Cardiovascular Disease | $202,278.31 |
| Gregory Pokrywka | Towson, MD | Internal Medicine | $183,820.69 |
| David Strobl | Lansing, MI | Cardiovascular Disease | $161,412.67 |
| Payal Kohli | Aurora, CO | Cardiovascular Disease | $160,572.72 |
| Paul Cohen | New York, NY | Cardiovascular Disease | $159,540.75 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.